Figure S1  Marker methylation levels in purified leukocytes. Plotted are $\beta$-values of the identified markers in seven cell types isolated from blood samples of six healthy men Reinius et al. (2012). Abbreviated cell types: NE neutrophils, EO eosinophils, MO monocytes, CD4+ T cells, CD8+ T-cells, NK natural killer cells, B CD19+ B lymphocytes.
PubMed search terms:

( "Early Detection of Cancer"[MeSH Heading]
  AND "DNA Methylation"[MeSH Heading]
  AND "Biological Markers"[MeSH Heading]
)
OR ( 
  ( 
    "cancer"[Title/Abstract]
    OR "neoplasms"[Title/Abstract]
    OR "malignancies"[Title/Abstract]
    OR "carcinoma"[Title/Abstract]
  )
  AND ( 
    "blood"[Title/Abstract]
    OR "leukocytes"[Title/Abstract]
    OR "buffy coat"[Title/Abstract]
  )
  AND ( 
    ( 
      "methylation"[Title/Abstract]
      AND ( 
        "epigenetic"[Title/Abstract]
        OR "epigenome"[Title/Abstract]
      )
    )
    OR "CpG"[Title/Abstract]
    OR "450K"[Title/Abstract]
    OR "Infinium"[Title/Abstract]
  )
  AND ( 
    "marker"[Title/Abstract]
    OR "biomarker"[Title/Abstract]
    OR "diagnosis"[Title/Abstract]
    OR "detection"[Title/Abstract]
    OR "screening"[Title/Abstract]
  )
)
AND ("2011/01/01"[PDat] : "2016/06/31"[PDat])
<table>
<thead>
<tr>
<th>Publication</th>
<th>Cancer</th>
<th>Markers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wu (2016)</td>
<td>Hepatocellular carcinoma</td>
<td>cg12680131, cg22511877</td>
</tr>
<tr>
<td>Roos et al. (2016)</td>
<td>Various</td>
<td>cg02444695, cg26079695, cg27094856, cg21046959</td>
</tr>
<tr>
<td>Konecny et al. (2016)</td>
<td>Lung cancer</td>
<td>SHOX2</td>
</tr>
<tr>
<td>Ho et al. (2015)</td>
<td>Colorectal adenomas</td>
<td>DNMT3B</td>
</tr>
<tr>
<td>Guo et al. (2016)</td>
<td>Esophageal squamous cell carcinoma</td>
<td>RASSF2</td>
</tr>
<tr>
<td>Joyce et al. (2015)</td>
<td>Various</td>
<td>IFNG, ICAM1, IL6</td>
</tr>
<tr>
<td>Cordero et al. (2015)</td>
<td>Colorectal and breast cancer</td>
<td>No hits for CRC</td>
</tr>
<tr>
<td>Dauksa et al. (2014)</td>
<td>Gastric cancer</td>
<td>APC, DAPK1, BCL2, CD44, TNFRSF10C, ACIN1</td>
</tr>
<tr>
<td>Yang et al. (2015)</td>
<td>Breast cancer</td>
<td>HYAL2</td>
</tr>
<tr>
<td>Winham et al. (2014)</td>
<td>Ovarian cancer</td>
<td>cg04389426, cg05674150</td>
</tr>
<tr>
<td>Tahara et al. (2013)</td>
<td>Gastric cancer</td>
<td>SFRP1</td>
</tr>
<tr>
<td>You et al. (2013)</td>
<td>Nasopharyngeal carcinoma</td>
<td>CDK10</td>
</tr>
<tr>
<td>Hajikhan Mirzaei et al. (2012)</td>
<td>Breast cancer</td>
<td>RHOBTB2</td>
</tr>
<tr>
<td>Xu et al. (2013)</td>
<td>Breast cancer</td>
<td>cg17378989, cg10237911, cg22385477, cg08287471, cg13905388</td>
</tr>
<tr>
<td>Heyn et al. (2013)</td>
<td>Breast cancer</td>
<td>cg15652666</td>
</tr>
<tr>
<td>Langevin et al. (2012)</td>
<td>Head and neck cancer</td>
<td>FGD4, SERPINF1, CIAO1, IL27, HYAL2, PLEKHA6</td>
</tr>
<tr>
<td>Bosviel et al. (2012)</td>
<td>Breast cancer</td>
<td>BRCA1</td>
</tr>
<tr>
<td>You et al. (2012)</td>
<td>Esophageal squamous cell carcinoma</td>
<td>PTPRO</td>
</tr>
<tr>
<td>Marsit et al. (2011)</td>
<td>Bladder cancer</td>
<td>NLRP4, BDKRB1, ATG2B, COX7C, ZNF322B, HIGD2A, TBCA, BRD7, PSME2</td>
</tr>
</tbody>
</table>

*Performed adjustment for leukocyte composition*
References (Supplement)


